Samsung Bioepis Signs Research Collaboration MOU with Chinese Biotech Innovation Center

Research and Development Collaboration with China's ATLATL Innovation Center

On April 29, Samsung Bioepis announced that it had signed a memorandum of understanding (MOU) with Atlatl Innovation Center, a Chinese bio research and development and innovation platform company, to officially launch its global open innovation business.

A view of the Samsung Bioepis building in Yeonsu-gu, Incheon. Samsung Bioepis

Atlatl Innovation Center is Asia's largest biotech incubation center, supporting technological innovation and business acceleration by facilitating research collaborations between biotech ventures and global companies. It operates bases in major bio clusters such as Beijing, Shanghai, Singapore, and Australia, providing shared laboratories, office space, and CRO (contract research organization) services.

Through this agreement, Samsung Bioepis plans to select promising biotech companies and support their early growth by helping them move into and conduct research at Atlatl Innovation Center.

This agreement marks the first time Samsung Bioepis is pursuing a business partnership with an overseas open innovation specialist institution. The company aims to secure next-generation promising bio technologies based on various modalities (therapeutic approaches) at an early stage going forward.

Seo Minjeong, Head of Open Innovation at Samsung Bioepis (Executive Director), said, "Global cooperation is essential for innovation in bio technology development, and through this partnership, we will be able to further accelerate the discovery and research of next-generation bio technologies leveraging state-of-the-art infrastructure and expertise."

This content was produced with the assistance of AI translation services.